News|Articles|November 17, 2026

FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer

Author(s)Russ Conroy

Data from the phase 1/2 ALKOVE-1 trial support the FDA approval of neladalkib in this non–small cell lung cancer population.

The FDA has approved neladalkib (Nelkarmi) as a treatment for patients with ALK-positive non–small cell lung cancer (NSCLC) previously managed with tyrosine kinase inhibitors (TKIs), according to a news release from the agency.1 The approval covers 2 indications:

  • those who received 1 prior ALK TKI consisting of alectinib (Alecensa),
  • or those who were given 2 or more prior ALK TKIs and platinum-based chemotherapy.

What data supported the approval of neladalkib?

The FDA based its decision on data from the phase 1/2 ALKOVE-1 study (NCT05384626), which evaluated neladalkib among patients with NSCLC and other solid tumors harboring ALK positivity. Topline data revealed that among patients who received one prior ALK TKI consisting of alectinib (n =67), the overall response rate (ORR) was 49% (95% CI: 37%-62%); 76% of responding patients had a duration of response (DOR) of 6 months or greater, and 52% had a DOR of at least 12 months.

Investigators previously presented results from the ALKOVE-1 trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.2 At the time of the analysis, neladalkib yielded an ORR of 31% (95% CI, 26%-37%) and a complete response (CR) rate of 2% among patients with advanced ALK-positive NSCLC who received any prior ALK TKI (n = 63). Additional data showed an ORR of 46% (95% CI, 33%-59%) and a CR rate of 5% among those with no prior receipt of lorlatinib (Lorbrena; n = 63); these rates were 26% (95% CI, 20%-33%) and 2%, respectively, among those who previously received lorlatinib (n = 190).

The median progression-free survival (PFS) was 5.7 months (95% CI, 4.4-6.5) in the any prior TKI population, 14.5 months (95% CI, 4.8-not evaluable [NE]) in the lorlatinib-naive population, and 4.6 months (95% CI, 2.8-6.2) in the lorlatinib-experienced population. The median DOR across each group was not reached (NR; 95% CI, 14.5-NE), NR (95% CI, 14.5-NE), and 17.6 months (95% CI, 6.9-NE). The intracranial ORR was 32% (95% CI, 22%-42%), 63% (95% CI, 41%-81%), and 21% (95% CI, 12%-32%) in each respective group.

Neladalkib is recommended for a dose of 150 mg orally once daily with or without food taken in the absence of disease progression or unacceptable toxicity.

What were the safety findings for neladalkib?

In the ALKOVE-1 trial, the most common any-grade treatment-emergent adverse effects (TEAEs) among patients who received neladalkib included alanine aminotransferase increases (47%), aspartate aminotransferase increases (44%), constipation (28%), dysgeusia (23%), and peripheral edema (18%). Dose reductions due to TEAEs occurred among 17% of patients, and 5% discontinued study therapy due to TEAEs. The investigators noted that the overall safety profile was consistent with avoiding tropomyosin receptor kinase–related neurotoxicities.

“In these data from the ALKOVE-1 study of TKI-pretreated patients with advanced [ALK-positive] NSCLC, neladalkib demonstrated a clinical profile consistent with its design goals,” lead study investigator Jessica Jiyeong Jiyeong Lin, MD, an attending physician in the Center for Thoracic Cancers and Henri and Belinda Termeer Center for Targeted Therapies at Mass General Brigham, and an associate professor of medicine at Harvard Medical School, concluded with coauthors in the presentation at ASCO.2

Neladalkib’s prescribing information includes warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. The most common adverse reactions occurring in at least 20% of patients included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue.

How was the ALKOVE-1 trial designed?

In the global first-in-human ALKOVE-1 trial, 253 patients who previously received TKIs for ALK-positive NSCLC received neladalkib at escalating doses ranging from 15 to 200 mg once daily. The primary end point of the phase 2 portion of the trial was ORR per blinded independent central review. Secondary end points included DOR, time to response, PFS, overall survival, intracranial activity, and safety and tolerability.

Across the TKI-pretreated population, the median age was 56 years (range, 24-83), and most patients were female (57%). Additionally, most patients had no history of smoking (66%) and an ECOG performance status of 1 (64%).

Previously, the FDA granted priority review to neladalkib as a treatment for this ALK-positive NSCLC population in May 2026 based on data from the ALKOVE-1 trial.3 The agency originally assigned a Prescription Drug User Fee Act date of November 27, 2026.

References

  1. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. News release. FDA. November 17, 2026. Accessed November 17, 2026. https://tinyurl.com/3v9pkhcv
  2. Lin JJ, Felip E, Cho BC, et al. ALKOVE-1: efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. J Clin Oncol. 2026;44(suppl 16):8503. doi:10.1200/JCO.2026.44.16_suppl.8503
  3. Nuvalent announces key program and business updates, strengthening foundation for global leadership in ROS1- and ALK-positive NSCLC. News release. Nuvalent, Inc. May 27, 2026. Accessed November 6, 2026. https://tinyurl.com/4843y6yp

Related to this article